Stevanato’s U.S. subsidiary OMPI of America scored a $95 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to expand its drug vial manufacturing operations in Indiana.
The OMPI plant in Fishers, Indiana, will ramp up its operations to produce both standard and EZ-fill vials for BARDA and its partners to meet current and future pandemic vaccine needs, the company said.
Italy-based Stevanato has estimated it supplies glass vials and syringes to about 90% of the currently marketed COVID-19 vaccine programs.
As part of the government contract, Stevanato will give priority access to designated BARDA vaccine and drug development partners when needed.
“We believe this investment will rapidly accelerate and scale Stevanato Group’s capacity in Indiana and further expand our growth in this key strategic market,” Franco Moro, Stevanato’s chief executive, said in a statement.
RELATED: Stevanato IPO raises $672M to fund biologics, vaccine delivery
Stevanato, which raised $672 million in a public offering in late July, has spent the past few years building its portfolio of drug delivery systems that include a pen injector, an auto-injector, an inhaler and a wearable delivery system.
In early February, Stevanato announced it expanded its license deal for Haselmeier’s Axis-D pen injector to include conditions like obesity, cardiovascular disease, gastrointestinal and neurological disorders, pain and arthritis. Stevanato first signed a licensing deal with Haselmeier in 2019 to use the injector technology for diabetes.
Stevanato has been battling for market share in the segment with SHL Medical, Ypsomed Selfcare Solutions, West Pharma and Becton Dickinson.